TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome[L31673,A228793,A228798], and current studies are exploring downstream effects of its…